Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function

European Journal of Pharmacology

Volumn 626, Issue 2-3, 2010, Pages 193-199

  Rojas, Camilo ^a   Thomas, Ajit G ^a   Alt, Jesse ^a   Stathis, Marigo ^a   Zhang, Jie ^b   Rubenstein, Edward B ^c   Sebastiani, Silvia ^d   Cantoreggi, Sergio ^d   Slusher, Barbara S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Profectus Biosciences   (United States)

^c Medical and Commercial Development Solutions Inc   (United States)

^d HELSINN HEALTHCARE SA   (Switzerland)

Author keywords

5 HT3 receptor; Granisetron; Ondansetron; Palonosetron; Receptor internalization

Indexed keywords

CELL SURFACE PROTEIN; CYAN FLUORESCENT PROTEIN; GRANISETRON; ONDANSETRON; PALONOSETRON; SEROTONIN 3 RECEPTOR;

ARTICLE; CELL FREE SYSTEM; CELL MEMBRANE; CONTROLLED STUDY; DISSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG INTERACTION; DRUG LABELING; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INCUBATION TIME; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TRANSPORT;

ANIMALS; CELL LINE; CELL MEMBRANE; CELL-FREE SYSTEM; GRANISETRON; HUMANS; ISOQUINOLINES; ISOTOPE LABELING; MICROSCOPY, FLUORESCENCE; PROTEIN TRANSPORT; QUINUCLIDINES; RECEPTORS, SEROTONIN, 5-HT3; SUBSTRATE SPECIFICITY; TIME FACTORS; TRITIUM;

EID: 70649090118     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.002     Document Type: Article

References (26)

1. Aapro M.S., Grunberg S.M., Manikhas G.M., Olivares G., Suarez T., Tjulandin S.A., Bertoli L.F., Yunus F., Morrica B., Lordick F., and Macciocchi A. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol. 17 (2006) 1441-1449
2. Bonhaus D.W., Stefanich E., Loury D.N., Hsu S.A., Eglen R.M., and Wong E.H. Allosteric interactions among agonists and antagonists at 5-hydroxytryptamine3 receptors. J. Neurochem. 65 (1995) 104-110
3. Decker G.M., DeMeyer E.S., and Kisko D.L. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J. Support. Oncol. 4 35-41 (2006) 52
4. Dubin A.E., Huvar R., D'Andrea M.R., Pyati J., Zhu J.Y., Joy K.C., Wilson S.J., Galindo J.E., Glass C.A., Luo L., Jackson M.R., Lovenberg T.W., and Erlander M.G. The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. J. Biol. Chem. 274 (1999) 30799-30810
5. Eisenberg P., Figueroa-Vadillo J., Zamora R., Charu V., Hajdenberg J., Cartmell A., Macciocchi A., and Grunberg S. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98 (2003) 2473-2482
6. Freeman S.L., Glatzle J., Robin C.S., Valdellon M., Sternini C., Sharp J.W., and Raybould H.E. Ligand-induced 5-HT3 receptor internalization in enteric neurons in rat ileum. Gastroenterology 131 (2006) 97-107
7. Geling O., and Eichler H.G. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J. Clin. Oncol. 23 (2005) 1289-1294
8. Glennon R.A., and Dukat M. Serotonin receptors and drugs affecting serotonergic neurotransmission. In: Lemke T.L., Williams D.A., Roche V.F., and Zito S.W. (Eds). Foye's Principles of Medicinal Chemistry, sixth ed. Wolters Kluwer/Lippincott Williams & Wilkins, New York, Y (2008) 434
9. Gralla R., Lichinitser M., Van Der Vegt S., Sleeboom H., Mezger J., Peschel C., Tonini G., Labianca R., Macciocchi A., and Aapro M. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. 14 (2003) 1570-1577
10. Haigler H.T., Maxfield F.R., Willingham M.C., and Pastan I. Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. J. Biol. Chem. 255 (1980) 1239-1241
11. Hesketh P.J. Chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 358 (2008) 2482-2494
12. Ilegems E., Pick H.M., Deluz C., Kellenberger S., and Vogel H. Noninvasive imaging of 5-HT3 receptor trafficking in live cells: from biosynthesis to endocytosis. J. Biol. Chem. 279 (2004) 53346-53352
13. Kao J.P. Practical aspects of measuring [Ca2+] with fluorescent indicators. Methods Cell Biol. 40 (1994) 155-181
14. Li J., Xia Y., and Kuter D.J. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br. J. Haematol. 106 (1999) 345-356
15. Lin J.W., Ju W., Foster K., Lee S.H., Ahmadian G., Wyszynski M., Wang Y.T., and Sheng M. Distinct molecular mechanisms and divergent endocytotic pathways of AMPA receptor internalization. Nat. Neurosci. 3 (2000) 1282-1290
16. Neijt H.C., Plomp J.J., and Vijverberg H.P. Kinetics of the membrane current mediated by serotonin 5-HT3 receptors in cultured mouse neuroblastoma cells. J. Physiol. 411 (1989) 257-269
17. Nelson D.R., and Thomas D.R. [3H]-BRL 43694 (Granisetron), a specific ligand for 5-HT3 binding sites in rat brain cortical membranes. Biochem. Pharmacol. 38 (1989) 1693-1695
18. Roettger B.F., Ghanekar D., Rao R., Toledo C., Yingling J., Pinon D., and Miller L.J. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol. Pharmacol. 51 (1997) 357-362
19. Rojas C., Stathis M., Thomas A.G., Massuda E.B., Alt J., Zhang J., Rubenstein E., Sebastiani S., Cantoreggi S., Snyder S.H., and Slusher B. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth. Analg. 107 (2008) 469-478
20. Simantov R., and Sachs L. Regulation of acetylcholine receptors in relation to acetylcholinesterase in neuroblastoma cells. Proc. Natl. Acad. Sci. U. S. A. 70 (1973) 2902-2905
21. Stoltz R., Cyong J.C., Shah A., and Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J. Clin. Pharmacol. 44 (2004) 520-531
22. Thompson A.J., and Lummis S.C. The 5-HT3 receptor as a therapeutic target. Expert Opin. Ther. Targets 11 (2007) 527-540
23. Vitalis B., Sebestyen L., Sike M., Solyom S., and Harsing Jr. L.G. Binding characteristics of GYKI-46 903, a non-competitive ligand at 5-HT3 receptors. Pharmacol. Res. 43 (2001) 291-299
24. Wong E.H., Clark R., Leung E., Loury D., Bonhaus D.W., Jakeman L., Parnes H., Whiting R.L., and Eglen R.M. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br. J. Pharmacol. 114 (1995) 851-859
25. Yan D., Schulte M.K., Bloom K.E., and White M.M. Structural features of the ligand-binding domain of the serotonin 5HT3 receptor. J. Biol. Chem. 274 (1999) 5537-5541
26. Yoshizawa, H., Saito, M., Aogi, K., Sekine, I., Yanagita, Y., Sakai, H., Inoue, K., Kitagawa, C., Ogura, T., Mitsuhashi, S., 2008. Palonosetron (Palo) is more effective than granisetron (G) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with cisplatin (CDDP)- or anthracycline plus cyclophosphamide (AC/EC)-based regimens: results of a phase III trial - Palo Japanese Cooperative Study Group Annals of Oncology 19, viii275.